In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brexit Effect On UK Medtech: View From The US

Executive Summary

A few short weeks after the UK public voted in favor of leaving the EU – and several high-profile political casualties later – the issue is not yet of the Brexit dust settling, but of nervous preparations for when it will. Economic commentators, weighed down by news overkill, say that the true indications of what lies ahead are at least another month away: bad news indeed for those who find the short-term ride plenty bumpy enough.

You may also be interested in...

Brexit Effects On Medtech: View From Switzerland

While medtech trading economies and major exporting firms agonize over the effects that Brexit will have on their own future prospects, Switzerland, small in geographic terms but a major player in medtech and the global health care products industries generally, has been among the first to quantify its concerns.

The Sensational Trumps Sense As UK Voters Show Appetite For “Brexit”

As night turned to day on June 24, it became clearer by the hour that the unthinkable had happened, and the UK’s long and acrimonious debate about its 43-year membership of the European Union had ended in a victory for the Leave group. The local health care products industries made their views clear some weeks ago, but today and in the months to come, they will have to confront a Plan B that was never in the plans.

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts